Aadi生物科学的短期利息下跌了13.7%,而Aldeyra治疗学的短期利息上升了8.2%。 Aadi Bioscience's short interest fell 13.7%, while Aldeyra Therapeutics saw an 8.2% rise in short interest.

Aadi Bioscience是一家生物制药公司,开发基因界定癌症的治疗方法。 1月,该公司的短期利息下降13.7%,少了472 700股。 Aadi Bioscience, a biopharmaceutical company developing therapies for genetically defined cancers, saw its short interest drop by 13.7% in January, with 472,700 shares shorted. 机构投资者现在拥有52.08%的股票。 Institutional investors now own 52.08% of the stock. 另一家生物技术公司Aldeyra治疗技术公司短期利息增加了8.2%,达到384万股,重点是免疫媒介疾病的治疗。 Aldeyra Therapeutics, another biotech firm, experienced an 8.2% rise in short interest to 3.84 million shares, with a focus on therapies for immune-mediated diseases.